ACPE 2026

ISPE'S 18TH ASIAN CONFERENCE ON PHARMACOEPIDEMIOLOGY

30 OCT - 1 NOV 2026 | MELBOURNE, AUSTRALIA

Conference Program Book

ispe International Society for Pharmacoepidemiology

MONASH University

MONASH INSTITUTE OF PHARMACEUTICAL SCIENCES



Welcome Message

From the ACPE2026 Local Host Committee and Conference Co-Chair



Dear Colleagues and Friends,

It is my great pleasure to welcome you to Melbourne for the 18th Asian Conference on Pharmacoepidemiology (ACPE2026), hosted by the Centre for Medicine Use and Safety (CMUS) at Monash University, in partnership with the International Society of Pharmacoepidemiology (ISPE).

This year's theme, *Data to Decisions: Real-World Evidence in Action*, highlights the importance of translating pharmacoepidemiologic research into meaningful improvements in clinical practice, medicines policy, and public health. ACPE2026 brings together researchers, clinicians, policymakers, and industry partners from across the Asia-Pacific region and beyond to share knowledge, explore methodological advances, and strengthen collaborations that help turn real-world evidence into better decisions and outcomes.

I hope the scientific programme and opportunities for discussion will inspire new ideas, encourage knowledge exchange, and foster meaningful connections, particularly among the next generation of pharmacoepidemiology researchers.

On behalf of the Local Host Committee, I warmly welcome you to Melbourne. We are delighted to host you in our vibrant, multicultural city and hope you enjoy both the conference and your time here.

I would like to sincerely thank ISPE, our speakers, sponsors, and everyone who has contributed to making ACPE2026 possible. Most importantly, thank you for joining us and contributing to this important meeting.

I wish you all a stimulating, productive, and enjoyable ACPE2026.

Warm regards,

Associate Professor Jenni Ilomäki
Local Host Committee Chair and Conference Co-Chair
Centre for Medicine Use and Safety
Monash Institute of Pharmaceutical Sciences
Monash University, Australia

Welcome Message



From the Chair, ACPE International Steering Committee and Conference Co-Chair

Dear Colleagues and Friends,

On behalf of the International Steering Committee and the Program Committee, it is my pleasure to welcome you to the 18th Asian Conference on Pharmacoepidemiology (ACPE2026) in Melbourne.

Over the years, ACPE has brought together colleagues across Asia and beyond to share knowledge and build lasting collaborations. Its growth reflects the dedication of successive hosts, organisers, and participants, alongside the development of research teams and scientific capacity across our region.

I hope this year's meeting will continue this tradition of learning and collaboration. I particularly welcome students and early-career researchers, whose ideas and contributions will shape the future of our field.

My sincere thanks go to Jenni Ilomäki, the Local Host Committee, and our colleagues at Monash University for bringing ACPE2026 together. I also thank my fellow Program Committee members and the abstract reviewers for shaping the scientific programme, and all speakers and participants for their contributions.

I wish you all an inspiring and rewarding conference.

Professor Hiraku Kumamaru
Conference Co-Chair
ACPE International Steering Committee Chair

Welcome Message

From ISPE President



On behalf of the International Society for Pharmacoepidemiology (ISPE), it is my great pleasure to welcome you all to the 18th Asian Conference on Pharmacoepidemiology (ACPE) in Melbourne!

We are delighted to co-host this meeting together with Monash University. This partnership reflects the strength of collaboration between institutions, and the value of open exchange, shared learning, and mutual support in advancing pharmacoepidemiology.

The theme of this year's conference, *Data to Decisions: Real-World Evidence in Action*, speaks directly to the work in front of us. Real-world evidence now carries weight in regulatory review, health technology assessment, guideline development, and everyday clinical care. That role brings responsibility: methods that withstand scrutiny, transparency about data and assumptions, and a clear understanding of the decisions our evidence is meant to inform.

This year's conference brings together researchers, practitioners, and experts from across Asia and around the globe. Throughout the meeting, you will have the opportunity to deepen your knowledge through engaging educational sessions, gain fresh insights from keynote lectures and symposia, and explore the breadth of research presented in our paper sessions.

Equally important, ACPE is a place to connect with colleagues, meet new friends, and lay the foundation for future collaborations. I warmly encourage you to take part in the social programme. And beyond the conference itself, Melbourne offers a great deal to enjoy: a city of laneways and galleries, generous parks and gardens, a serious coffee culture, and a food scene drawn from all over the world.

I would like to warmly thank the organisers of the conference, and especially the conference co-chairs, Professor Hiraku Kumamaru from Yokohama City University and Associate Professor Jenni Ilomäki from Monash University, for their outstanding efforts and dedication in making this conference a success. Special thanks are due to Associate Professor Ilomäki, who also serves as Chair of the Local Host Committee.

Representing ISPE in Melbourne is a privilege, and I look forward in equal measure to learning from the work to be presented and to the conversations it will start.

We are thrilled to welcome you, not only to this conference but also to a community dedicated to advancing our field together.

Welcome to Melbourne, and welcome to the 18th Asian Conference on Pharmacoepidemiology!

Warm regards,

Daniela C. Moga, MD, PhD, FISPE
President of ISPE

ispe International Society for Pharmacoepidemiology

Conference Venue

Friday 30 October – Sunday 1 November

Monash University

Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences

381 Royal Parade, Parkville VIC 3052





Conference Venue

Friday 30 October – Sunday 1 November

Sissons Building (401)	
Monash Connect, G/F	Registration Spotlight Posters
Cossar Hall, G/F	Catering Posters Welcome Reception
Lecture Theatre 1, 1/F	Conference Opening and Welcome Address Keynote Presentation: Juliet Gerrard Contributed Paper Sessions Symposia Sessions Keynote Presentation: Brian Strom Award Presentations and Conference Close
Lecture Theatre 2, 1/F	Contributed Paper Sessions
Lecture Theatre 5, 1/F	Contributed Paper Sessions Symposia Sessions
Lecture Theatre 3, 2/F	Contributed Paper Sessions Symposia Sessions AsPEN Showcase
Scott Building (402)	
Cafeteria, G/F	Catering Posters
PPS 1, 1/F	Educational Session – Track B
PPS 2, 1/F	Educational Session – Track C
CLS 1, 1/F	Educational Session – Track A SIG Meeting - Environmental
CLS 2, 1/F	Educational Session – Track D SIG Meeting - Drug Utilisation Research (DUR)
CLS 3, 1/F	SIG Meeting - Cancer
CLS 4, 1/F	SIG Meeting - AsPEN
Manning Building	
G05 G/F	Speaker Preparation Room
Building 407	
Hercules Room, 1/F	ISPE Board Meeting

General information

Wi-Fi

Visitors may choose to use "Monash Guest Wi-Fi" whilst on campus. You will be prompted to login or create a guest account to connect. Please view the link below for more details:

https://www.monash.edu/esolutions/network/guest-wi-fi

Catering

Morning and afternoon tea and lunches will be provided on Saturday 31 October and Sunday 1 November.

To assist with delegate flow and comfort, catering stations will be located over two rooms

and spaces, being the Cafeteria, G/F and Cossar Hall, G/F.

Registration

Upon arrival, please enter the Sissons Building (401) via Royal Parade and proceed to the registration desk located in Monash Connect to collect your name badge.

You MUST wear your name badges at all times for access to the conference.

Certificate of Attendance

Attendees will be emailed a certificate of attendance following the conclusion of the conference.

If you presented a poster or contributed oral paper, this will be included on your certificate.

SIM cards

Local SIM cards can be purchased at various convenience stores and supermarkets.

Organising Committees

Local Host Committee

Jenni Ilomäki (ACPE Co-Chair)	**Shaun Lee**	**Richeek Pradhan** (Lead, Educational Session Program)
Simon Bell	**Yannee Liu**	**Dinesh Sangarran Ramachandram**
Annie Ea	**Uru Malik**	**George Tan**
Demi He	**Thu Hang Nguyen**	**Michelle Tan**
Hayato Kizaki	**Leonie Picton**	**Sam Wade**
Edward Lau	**Lisa Pont**	**Grace Wangge**

Program Committee

Jenni Ilomäki (ACPE Co-Chair)
Monash University

Hiraku Kumamaru (ISC Chair and ACPE Co-Chair)
Yokohama City University

Zanfina Ademi
Monash University

Ben Bates
Rutgers University

Simon Bell
Monash University

Joe Blais
The University of Hong Kong

Harsha Chalasani
JSS College of Pharmacy

Celine Chui
The University of Hong Kong

Ben Daniels
UNSW Sydney

Edward Lai
National Cheng Kung University

Hu Li
Neurocrine

Kai-Li Liaw
Merck

Joshua Lin
Harvard Medical School

Minako Matsumoto
Keio University

Frank May (ISC Past Chair)
RGHPCS

Juliana de Oliveira Costa
UNSW Sydney

Richeek Pradhan
Monash University

Soko Setoguchi (ISC Past Chair)
Rutgers University

Judy Shin
Seoul National University

George Tan
Monash University

Krishna Undela
NIPER

Yanmin Zhu
Brigham and Women's Hospital

ISPE ACPE International Steering Committee

(2025 – 2026)

Hiraku Kumamaru
(ISC Chair and ACPE Co-Chair)
Yokohama City University

Keiko Asao
Kappa Medical

Ben Bates
Rutgers University

Arnold Chan
TriNetX

Esther Chan
The University of Hong Kong

Nam-Kyong Choi
Ehwa Women's University Korea

Jennifer Christian
Evinexus

Mike Du
University of Oxford

Jian-Yu (Jerry) E
Sanofi Genzyme

Nicholas Everage
(ISPE Vice President/Finance)
Biogen

Kirk Geale
Quantify Research

Parthasarathi Gurumurthy
Pharmacovigilance Program

Jenni Ilomäki (ACPE Co-Chair)
Monash University

Nakyung Jeon

Yea-Huei Kao Yang
National Cheng Kung University

Avinash Khadela
Parul University

Ursula Kirchmayer (ISPE Immediate Past-President)
Lazio Regional Health Service

Kiyoshi Kubota
Drug Safety Research Unit Japan

Edward Lai
National Cheng Kung University

Suk-Hyang Lee
Ajou University

Hu Li
Neurocrine

Kai-Li Liaw
Merck Inc.

Joshua Lin
Harvard Medical School

Meiyou Liu
4th Military Hospital University

Frank May (ISC Co-Vice Chair)
RGHPCS

Jingping Mo
Pfizer

Daniela Moga (ISPE President)
University of Kentucky

Nobuhiro Ooba
The Nihon University School of Pharmacy

Byung Joo Park
Korea Institute of Drug Safety & Risk Management

Sallie Pearson
University of New South Wales

Syd Phillips
QuintilesIMS

Lisa Pont
University of Technology Sydney

Mary Beth Ritchey
Med Tech Epi

Maribel Salas
ISPE Global Development Committee

Savitha Sanathan
JSS College of Pharmacy

Soko Setoguchi (ISC Co-Vice Chair)
Rutgers University

Laura Simmons
International Society for Pharmaceutical Engineering

Masato Takeuchi
Shizuoka Graduate University of Public Health

Shiro Tanaka
Kyoto University

Krishna Undela
National Institute of Pharmaceutical Education and Research (NIPER)

Yoshiaki Uyama
Pharmaceuticals and Medical Devices Agency

Sawaeng Watcharathanakij
Ubon Ratchathani University

Ian Chi Kei Wong
University of Hong Kong

Siyan Zhan
Peking University

Wei Zhou
Eli Lilly

Abstract reviewers

We extend our sincere thanks to all abstract reviewers for their valuable contributions to ACPE 2026. Their expertise, thoughtful feedback and commitment to scientific excellence have played an important role in maintaining the high standard and quality of the conference program.

Ravinandan A P
Norazida Ab Rahman
Kenji Adachi
Alka Ahuja
Kamakshi Shriya Akalu
Hammad Al Dali
Suresh Tharayil Aman
Keiko Asao
Zhaohui Bai
Mohammad Bakhriansyah
Shamala Balan
Benjamin Bates
Jatin Batra
Claudia Becker
Ruby Benson
Mohitosh Biswas
Joseph Blais
Claudia Bruno
Gregory Calip
Yi Chai
Sri Harsha Chalasani
Sze Ling Chan
Dilip Chandrasekhar
Chi-Han Cheng
Franco Cheng
Manik Chhabra
Jignasa Chiramana
Yongtai Cho
Ka Chun Chong
Dujrudee Chonwong
Ping-Sheng Chou
Yu-Wen Chu
Albert Tzu-Ming Chuang
Sze Ling Celine Chui
Benjamin Daniels
Juliana de Oliveira Costa
Rakesh Dixit
Yaa-Hui Dong
chengxiang du
Jian-Yu (Jerry) E
Min Fan
Guoze Feng
Yang Feng
Neelima Ganzi
Ruonan Gao
Wijemuni Ishara Gayani De Silva
Jeesa George
Malcolm Gillies
Natasa Gisev
Shreya P Gudur
Shalak Gunjal
Vishwas H N
Rajesh Hadia
Jeff Harrison
Qingke Demi He
Xintong He
Omar Hegazi
Takehiro Hirai
Masayuki Hirose
Jun Ni Ho
Chethana Hosamalangi Suresha
Miyuki Hsing-Chun Hsieh
Rong Hua
Chun-Tse Hung
Jenni Ilomäki
MD FAKRUL ISLAM
Sudi Indra Jaya
Sanjay Jayaram
Minjeong Jeon
Nisha Jha
He Jin
Kyungyeon Jung
Wei Kang
Ruby Kasana
Avinash Khadela
bonggi kim
Ju Hwan Kim
Seok-Won Kim
Hwa Yeon Ko
Eshveen Kour
Kiyoshi Kubota
Hiraku Kumamaru
Prasanna Kumar
Litty Kunjumon
Ann Kuruvilla
Edward Lai
Yunfeng Lai
Jack Chi Him Lau
Kai-Li Law
Jasmine Lee
Wen Shi Lee
Yubin Lee
Hailong Li
Hu Li
Tong Li
Xinchi Li
Yuexi Liao
Audrey Lim
Hung-Wei Lin
Jialing Lin
Joshua Lin
Zhen-Fang Lin
Chia-Hung Liu
Lijia Liu
Yinghui Liu
Navin Kumar Loganadan
Tejashree M U
Raghava Kalyan Maddukuri
Ramesh Madhan
Venkatesh Madhugiri Prakash
Pravachana Malakapogu
Andrea Margulis
Minako Matsumoto
Colleen Maxwell
Frank May
Sonal Sekhar Miraj
Jingping Mo
Daniela Moga
Sri Ram Murugesh
Gokulavasa Nagarajan
Archana Navale
Giao Nguyen
Siqi Ni
Mamidi Niveditha
In-Sun Oh
Yusuke Okada
Suguru Okami
Zacchaeus Olofin
Danisha P
Ravindra P Choudhary
Shilpa Palaksha

Abstract reviewers (cont)

Pallavi Palasseri
Byung-Joo Park
Jaeyu Park
Imelda Peña
Lisa Pont
Basavaraj Ramappa Poojar
Richeek Pradhan
Rajeshwari Punekar
Rosy Raju
Darmendra Ramcharran
Sanika Rege
Mita Restinia
Ramin Rezaeianzadeh
Mary Beth Ritchey
Catherine Rogers Murray
Nurrul Salwa Saleh
Chiranjeev Sanyal
Rehan Sarwar
Balaji Sathyanarayana Gupta
Juny Sebastian
Shrey Seth
Vraj B Shah
Atiqulla Shariff
Cheng-Chan Shih
Ju-Young Shin
Han-Wei Shiu
Tomokazu Shoji
Meng Shu
Chloe CH Smit
Michael Steinbuch
Elizabeth Stettenbauer
Hsuan-Yu Su
Qi Sun
Jehath Syed
Albin T Thottankara
Sumaiya Taj
Masato Takeuchi
George Tan
Shiro Tanaka
Xinning Tong
Daniel Tsai
Krishna Undela
Sona Vincent
Santosha Vooradi
Eric Yuk Fai Wan
Shengfeng Wang
Grace Wangge
Sawaeng Watcharathanakij
Li Xie
Aimin Yang
Nan Yang
Shuei He Yang
Alfi Yasmina
See Hwee Yeo
Qiuyan Yu
Siu Chung Andrew Yuen
Huan Zhang
Yajin Zhao
Qishi Zheng
Yifan Zheng
Jifang Zhou
Wei Zhou
Bingbing Zhu
Yanmin Zhu
Che Zin

Educational Session Program

Friday 30 October 2026

TRACK A: Designing Transparent and Reproducible Real-World Drug Studies

(Beginners/Intermediate)

Session coordinators:

A/Prof Sze Ling Celine Chui, The University of Hong Kong

Dr Krishna Undela, NIPER Guwahati

Instructors:

Dr Franco Cheng, Postdoctoral Fellow, Hong Kong University/University of Auckland

Jack Lau, PhD Student, Hong Kong University

Eunice Kehui Deng, PhD Student, Hong Kong University

Dr George Tan, Adjunct Research Fellow, Monash University

Edward Lau, Student, University of Sydney

Dr Mary Beth Ritchey, Associate Research Professor from Rutgers University, Principal and Owner of MedTechEpi LLC, past president of ISPE

Dr Benjamin Daniels, Senior Research Fellow, University of New South Wales

Time	Topic
09:00 – 09:30 (30 min)	**Designing pharmacoepidemiologic studies from clinical questions** **Instructor: Dr Mary Beth Ritchey**
09:30 – 10:30 (60 mins)	**Principles of pharmacoepidemiology using large databases** **Instructor: A/Prof Sze Ling Celine Chui and Dr Franco Cheng**
10:30 – 11:00 (30 mins)	**BREAK**
11:00 – 12:30 (90 mins)	**Evaluation of clinical outcomes in healthcare databases** **Instructors: Dr Franco Cheng, Jack Lau and Eunice Kehui Deng**
12:30 – 13:30 (60 mins)	**LUNCH**
13:30 – 15:00 (90 mins)	**Best practices for AI-assisted research** **Instructors: Jack Lau and Eunice Kehui Deng**
15:00 – 15:30 (30 mins)	**BREAK**
15:30 – 17:00 (90 mins)	**Seeing is Understanding: Data Visualisation in Pharmacoepidemiology** **Instructors: Dr George Tan, Edward Lau, Dr Mary Beth Ritchey and Dr Benjamin Daniels**
17:00	**CLOSE**

Educational Session Program

Friday 30 October 2026

TRACK B: Emulating a Hypothetical Drug Trial Using Real-World Data (Advanced)

Session coordinator:

A/Prof Joshua Lin, Harvard Medical School

Instructors:

A/Prof Joshua Lin, Harvard Medical School
Prof Edward Lai, National Cheng Kung University
Dr Daniel Tsai, National Cheng Kung University
Dr Nathan Vidal, National Cheng Kung University
Dr Kenneth Mann, University College London
Dr Wallis Lau, University College London

Time	Topic
09:00 – 10:30 (90 mins)	**Applying Target Trial Emulation (TTE) in EHR and Claims Data: the general framework and fit-for-purpose database considerations** **Instructor:** Josh Lin **Implementation of TTE: Clone–Censor–Weight Approach** **Instructors:** Daniel Tsai and Nathan Vidal
10:30 – 11:00 (30 mins)	**BREAK**
11:00 – 12:30 (90 mins)	**Implementation of TTE: Clone–Censor–Weight Approach cont.** **Instructors:** Daniel Tsai and Nathan Vidal
12:30 – 13:30 (60 mins)	**LUNCH**
13:30 – 15:00 (90 mins)	**Implementation of TTE: Sequential Trials** **Instructors:** Kenneth Man and Wallis Lau
15:00 – 15:30 (30 mins)	**BREAK**
15:30 – 17:00 (90 mins)	**Recent developments and other advanced methods used for TTE with panel discussion** **Instructor:** Edward Lai **Recent Panel Discussion** **Instructors:** All speakers
17:00	**CLOSE**

Educational Session Program

Friday 30 October 2026

TRACK C: Machine Learning in Real-World Drug Studies: Introduction to Prediction and Natural Language Processing (NLP) models

Session coordinators:

Dr Yanmin Zhu, Brigham and Womens Hospital and Harvard Medical School

Dr Richeek Pradhan, Monash University

Instructors:

Dr Harvey Koh, Monash University

Dr Ting Xia, Monash University

Crystal Leung, Monash University

Time	Topic
09:00 – 10:30 (90 mins)	**Course Overview and Learning Objectives** **Instructor:** Dr Richeek Pradhan **The Roadmap from Conventional NLP to Large Language Models** **Instructor:** Dr Harvey Koh **Foundations of NLP for Real-World Data: Tasks, Models, and Research Applications** **Instructor:** Dr Ting Xia **Part 1: NLP coding Lab set-up** **Instructor:** Crystal Leung
10:30 – 11:00 (30 mins)	**BREAK**
11:00 – 12:30 (90 mins)	**Part 1 lab:** NLP Coding Laboratory: NLP Demonstration and Coding Exercises **Instructors:** Crystal Leung and Dr Ting Xia
12:30 – 13:30 (60 mins)	**LUNCH**
13:30 – 15:00 (90 mins)	**Practical LLM Applications in Pharmacoepidemiology and Pharmacovigilance** **Instructor:** Dr Yanmin Zhu **Part 2 lab: LLM Hands-On Laboratory: Extraction from Clinical and Safety Narratives** **Instructor:** Dr Harvey Koh
15:00 – 15:30 (30 mins)	**BREAK**
15:30 – 17:00 (90 mins)	**More Data, More Bias? Treading Carefully in Designing NLP- and LLM-Enabled Pharmacoepidemiology Research** **Instructor:** Dr Richeek Pradhan **Key Takeaways, Course Summary and Closing Remarks** **Instructor:** Dr Yanmin Zhu
17:00	**CLOSE**

Educational Session Program

Friday 30 October 2026

TRACK D: Learning from Real-World Evidence to Inform Policy and Practice

Session coordinator:

Prof Zanfina Ademi, Monash University

Instructors:

Dr Gopisankar Mohanannair Geethadevi, Monash University

Dr Melanie Lloyd, Monash University

Prof Olaf Klungel, Utrecht University

Dr Yeji Baek, Monash University

Time	Topic
09:00 – 10:30 (90 mins)	**Introduction** **Instructors:** Dr Gopisankar Mohanannair Geethadevi, Dr Melanie Lloyd **Real-world drug studies for regulatory decision making** **Instructor:** Prof Olaf Klungel **Discussion** **Instructor:** Dr Melanie Lloyd
10:30 – 11:00 (30 mins)	**BREAK**
11:00 – 12:30 (90 mins)	**Making trial-based economic evaluations fit for purpose using real-world evidence** **Instructor:** Dr Melanie Lloyd **Health economic modelling using real-world data – basics** **Instructor:** Dr Gopisankar Mohanannair Geethadevi
12:30 – 13:30 (60 mins)	**LUNCH**
13:30 – 15:00 (90 mins)	**Advanced health economic modelling techniques using real-world data** **Instructor:** Dr Gopisankar Mohanannair Geethadevi
15:00 – 15:30 (30 mins)	**BREAK**
15:30 – 17:00 (90 mins)	**Hands-on session on health economic modelling using real-world data** **Instructors:** Dr Gopisankar Mohanannair Geethadevi, Dr Melanie Lloyd and Dr Yeji Baek **Further questions and feedback collection** **Instructors:** Dr Gopisankar Mohanannair Geethadevi, Dr Melanie Lloyd and Dr Yeji Baek
17:00	**CLOSE**

Conference Program

Friday 30 October 2026

Educational Session Program (optional, additional fee)

Venue: Monash University
Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences
381 Royal Parade, Parkville VIC 3052

(PLEASE SEE INDIVIDUAL TRACK PROGRAMS FOR DETAILS)

Time	Registration and Information Desk Open
09:00 – 17:00	**TRACK A - Designing Transparent and Reproducible Real-World Drug Studies (Beginners/Intermediate)**
Room:	CLS 1
09:00 – 17:00	**TRACK B - Emulating a Hypothetical Drug Trial Using Real-World Data (Advanced)**
Room:	PPS 1
09:00 – 17:00	**TRACK C - Machine Learning in Real-World Drug Studies: Introduction To Prediction and Natural Language Processing (NLP) Models**
Room:	PPS 2
09:00 – 17:00	**TRACK D - Learning from Real-World Evidence to Inform Policy And Practice**
Room:	CLS 2
17:30 – 19:00	**Welcome Reception** Cossar Hall, Monash University

Saturday 31 October 2026

Day 1 – Saturday 31 October 2026				
07:30 – 17:00	**Registration and Information Desk Open**			
Room:	**Monash Connect**			
	Conference Opening and Welcome Address			
Room:	**Lecture Theatre 1**			
	Keynote Presentation			
	A front row seat: lessons learned at the intersection of science, policy, and politics **Prof Dame Juliet A. Gerrard DNZM, HonFRSC,** The University of Auckland			
09:45-10:25	**Morning Break / Exhibition / Poster Viewing**			
09:45-10:25	**SIG Meeting – Environment**	**SIG Meeting – DUR**	**SIG Meeting – Cancer**	**SIG Meeting – AsPEN**
Room:	**CLS 1**	**CLS 2**	**CLS 3**	**CLS 4**
10:30-12:00	**Symposium Session 1 - Privacy-Preserving Federated AI-Enabled Analytics for Regulatory Decision-Making: Bridging Innovation and Decision-Grade Evidence**	**Symposium Session 2 - Target Trial Emulations in Neurology and Mental Health**	**Symposium Session 3 - Advancing Medication Adherence Measurement in Pharmacoepidemiology: Leveraging Novel Datasets, Cutting-Edge Methods and Patient-Reported Perspectives**	**Contributed Paper Session 1 – Vaccine Safety Surveillance and Signal Detection**
Room:	**Lecture Theatre 3**	**Lecture Theatre 1**	**Lecture Theatre 5**	**Lecture Theatre 2**
	Moderators: **Dr Hsu-Wen Chou,** Pfizer **Presenters:** **Angela Yin,** IQVIA	**Moderators:** **Qingke Demi He,** Monash University **Dr George Tan,** Monash University	**Moderators:** **Dr Stella Talic,** Monash University **Speakers:** **Dr Stella Talic,** Monash University **Caroline Trin,** Monash University **Dr Lachlan Dalli,** Monash University **Dr Harvey Koh,** Monash University **Lubna Farhana,** Universitas Padjadjaran	**Moderators:** **Prof Jim Buttery,** Global Vaccine Data Network **A/Prof Sze Ling Celine Chui,** The University of Hong Kong
10:30–10:45	**Dr K. Arnold Chan,** TriNetX **Mary Beth Ritchey,** Med Tech Epi	**Speakers:** **Prof Li Wei,** University College London **A/Prof Ruth Brauer,** UCL **Daniel Tsai,** National Cheng Kung University **Prof Olaf Klungel,** Utrecht University		**100. Data-driven focal windows selection in self-controlled case series: COVID-19 vaccine case study** Norazida Ab Rahman, Utrecht University
10:45–11:00				**101. No signal left behind: multi-modal vaccine safety surveillance** Hazel Clothier, Murdoch Children's Research Institute

Day 1 – Saturday 31 October 2026		
11:00–11:15		**102. Influenza vaccination and septic shock in elderly heart failure patients** Kevin Yi-Chen Liao, National Cheng Kung University
11:15–11:30		**103. Integrating multi-method signal detection using Bayesian networks for enhanced vaccine safety surveillance** Md Samiullah, Murdoch Children's Research Institute
11:30–11:45		**104. A Multi-Datasource Investigation of a Consumer-Initiated Vaccine Safety Signal** Aishwarya Narendra Shetty, Murdoch Children's Research Institute
11:45–12:00		**105. mRNA COVID-19 Vaccination and Incident Autoimmune Disease** Kevin Yi-Chen Liao, National Cheng Kung University
12:00-13:25	**Lunch**	
12:15-13:25	**Poster Spotlight Session 1 (Please See Poster Program for Details)** **Group 1 – Effectiveness and Safety Outcomes** **Group 2 – Pharmacovigilance**	
Room:	**Monash Connect**	

Day 1 – Saturday 31 October 2026				
13:30-15:00	**Contributed Paper Session 2 – Diabetes and Obesity: Treatment Safety and Outcomes**	**Contributed Paper Session 3 – Cardiovascular–Kidney–Metabolic Therapeutics**	**Contributed Paper Session 4 – Cancer Treatment Effectiveness, Safety and Economics**	**Contributed Paper Session 5 - Psychotropic and ADHD Medication Safety**
Room:	**Lecture Theatre 3**	**Lecture Theatre 1**	**Lecture Theatre 5**	**Lecture Theatre 2**
	Moderators: **A/Prof Edwin Tan,** The University of Sydney **Prof Li Wei,** University College London	**Moderators:** **Prof Esther Wai Yin Chan,** The University of Hong Kong **Dr Lachlan Dalli,** Monash University	**Moderators:** **Prof Olaf Klungel,** Utrecht University **Dr Uru Malik,** Aurumetrics	**Moderators:** **Dr Ting Xia,** Monash University **Dr Kenneth Man,** University College London
13:30–13:45	**106. Risk assessment of herpes zoster associated with DPP-4 inhibitor in T2D patients** Allen Yu-Ching Chang, National Cheng Kung University	**112. Impact of Cardiovascular-Kidney-Metabolic Syndrome on Clinical Outcomes in Taiwan: A Retrospective Cohort Study** Hsi-Yu Lai, National Taiwan University	**118. Nationwide outpatient antineoplastic prescribing trends surrounding policy implementation in Japan** Dr Takehiro Ishida, Teikyo University	**124. Geographic variation of ADHD medicine use in Australian adults, 2019-2024** Dr Malcolm Gillies, University of New South Wales
13:45–14:00	**107. Semaglutide/Tirzepatide-Associated Myopathy and Rhabdomyolysis: Systematic Review and FAERS Disproportionality Analysis** Qingke Demi He, Monash University	**113. Early SGLT2i initiation and outcomes in ADHF without sustained dual guideline-directed therapy** Shu Chen Yang, National Taiwan University Hospital Yunlin Branch	**119. Phase-IV External-Comparator Superiority Trial of Immunotherapy-Based Regimens in Metastatic Driver Mutation-Negative NSCLC** Avinash Khadela, Parul University	**125. Association Between Methylphenidate Treatment and Psychiatric Hospitalization by Psychiatric Burden in ADHD** Dr Na-Young Jeong, Ewha Womans University
14:00–14:15	**108. SGLT-2i and Risk of Self-Harm in T2DM: A Target Trial Emulation Study** Yuhao Li, Peking University	**114. Treatment intensification in atherosclerotic cardiovascular disease: high-intensity statins versus ezetimibe add-on therapy** Pharm.D. Tzu-Yun Yang, National Taiwan University	**120. Association of chemotherapy dose intensity with clinical outcomes in early breast cancer** Chien-Kung Chen, National Taiwan University	**126. Methylphenidate–Antiseizure Drug-Drug Interactions Associated with Movement Disorders: Disproportionality Analysis Considering Concomitant Medication** Jiwon Kim, Ewha Womans University

Day 1 – Saturday 31 October 2026				
14:15–14:30	**109. Non-arteritic Anterior Ischemic Optic Neuropathy and GLP-1RAs in Non-Diabetic Individuals with Obesity** Chensyuan Ma, National Cheng Kung University	**115. Pharmacogenomic and Statin Response in UKB Primary Care: A Longitudinal Linear Mixed-Effects** Ike Dhiah Rochmawati, University of Glasgow	**121. Dual Immunotherapy Versus Pembrolizumab in Metastatic Head-Neck Cancer: An External Comparator Analysis** Dr Vraj Shah, L.M. College of Pharmacy	**127. Benzodiazepines versus Z-drugs and adverse outcomes among adolescents and young adults** Kyung Jin Lee, The University of Hong Kong
14:30–14:45	**110. HbA1c trajectories and associated factors in Thai patients with type 2 diabetes** Anuchit Sermhattakit, Ubon Ratchathani University	**116. Suboptimal LDL-C response to PCSK9 inhibitors: prevalence and risk factors** Bingbing Zhu, The University of Hong Kong	**122. Risk of colorectal cancer and GLP-1 RAs in type 2 diabetes** Han-wei Shiu, National Cheng Kung University	**128. Sleep-related prescribing cascades following ADHD medications in Korean adults** Eunsun Lim, Ewha Womans University
14:45–15:00	**111. Incidence of type 2 diabetes mellitus in men receiving finasteride and tamsulosin** Yuhao Li, Peking University	**117. Gabapentinoid use and risk of heart failure: a case-crossover and case-case-time-control study** Andrew S.C. Yuen, University College London	**123. Consumption and expenditure on lower ESMO-MCBS oncology medicines: a global drug-utilisation analysis** Xincheng Jiang, The University of Hong Kong	**129. Ethnic and socioeconomic differences in ADHD diagnosis and treatment in United Kingdom** Mubarek Nuru Ahmed, Aston University
15:00-15:25	**Afternoon Break / Exhibition / Poster Viewing**			
15:30-17:00	**Concurrent Symposium Session 4 - Beyond Traditional Cohorts: Within-Individual Designs for Drug Safety Research in Asia**	**Concurrent Symposium Session 5 - Counting What We Stop: Measuring Deprescribing in Older Adults with Real-World Data — from Global Methods to Asia-Pacific Practice**	**Concurrent Symposium Session 6 - Next-Generation Vaccine Pharmacovigilance: Real-World Evidence, AI and Global Collaboration**	**Contributed Paper Session 6 - Pregnancy and Intergenerational Medication Safety**
Room:	**Lecture Theatre 3**	**Lecture Theatre 1**	**Lecture Theatre 5**	**Lecture Theatre 2**
	Moderators: **A/Prof Amy HY Chan,** The University of Auckland **A/Prof Adrienne**	**Moderators:** **Danijela Gnjidic,** The University of Sydney **Dr Pui San Saw,** Monash University Malaysia	**Moderators:** **Dr Hazel Clothier,** Murdoch Children's Research Institute **Prof Jim Buttery,** Global Vaccine Data	**Moderators:** **Dr Yanmin Zhu,** Brigham and Women's Hospital and Harvard Medical School **A/Prof Luke Grzeskowiak,** Flinders University

Day 1 – Saturday 31 October 2026				
15:30–15:45	**Chan,** Aston University **Speakers:** **Prof Edward Lai,** National Cheng Kung University **Dr Kenneth Man,** University College London **Dr Andrew S.C. Yuen,** University College London **Dr Wallis Lau,** UCL **Prof Ju-young Shin,** Seoul National University	**Dr Daniela Moga,** University of Kentucky **Speakers:** **Danijela Gnjidic** **Dr Daniela Moga,** University of Kentucky **A/Prof Joshua Lin,** Harvard Medical School **Dr Mouna Sawan,** The University of Sydney **Prof Shaun Lee,** Monash University, Malaysia **A/Prof Grace Wangge,** Monash University, Indonesia **Dr Shin Liau,** Monash University	Network **Speakers:** **Daneeta Hennessy,** Murdoch Children's Research Institute **John Mallard,** Murdoch Children's Research Institute **Dr Aishwarya Narendra Shetty,** Murdoch Children's Research Institute **Dr Gerardo Luis Dimaguila,** Centre for Health Analytics **Dr Jarir At Thobari,** Universitas Gadjah Mada **Prof Jim Buttery,** Global Vaccine Data Network	**130. Risk of maternal infection and adverse birth outcomes following acid-suppressive medications use** Jisoo Cho, Seoul National University
15:45–16:00				**RISING STAR AWARDEE:** **131. Paternal Valproate Exposure and Neurodevelopmental Disorders in Children** Dr Eun-Young Choi, Sungkyunkwan University
16:00–16:15				**132. Prenatal paracetamol use and risks of ASD and ADHD among sibling-matched cohorts** Dr Shan Luo, The University of Hong Kong
16:15–16:30				**133. Maternal opioid prescriptions and subsequent risk of hospital admission in offspring** Yesol Yim, Kyung Hee University College of Medicine
16:30–16:45				**134. Ezetimibe exposure during early pregnancy and the risk of spontaneous abortion** Woo Hyeon Yoo, Sungkyunkwan University
16:45–17:00				**135. Benzodiazepine exposure during early pregnancy and risk of miscarriage** Dr Tomofumi Ishikawa, Tohoku University
18:00-22:30	**Conference Dinner**			
Venue:	Bong Su, Melbourne Zoo			

Conference Program

Sunday 1 November 2026

Day 2 – Sunday 1 November 2026				
07:30 – 16:00	**Registration and Information Desk Open**			
08:00-08:50	**AsPEN showcase**			
Room:	**Lecture Theatre 3**			
09:00-10:30	**Contributed Paper Session 7 - Opioids, Pain Medicines and Sedative-Related Harms**	**Contributed Paper Session 8 - Infectious Diseases, Antimicrobial Resistance and Treatment Outcomes**	**Contributed Paper Session 9 - Medicines Policy, Access and Economic Impact**	**Contributed Paper Session 10 - Quality Use of Medicines and Pharmacist-Led Interventions**
Room:	**Lecture Theatre 3**	**Lecture Theatre 1**	**Lecture Theatre 5**	**Lecture Theatre 2**
	Moderators: **Dr Vijay Suppiah,** Adelaide University **A/Prof Natasa Gisev,** UNSW Sydney	**Moderators:** **A/Prof Grace Wangge,** Monash University, Indonesia **Dr. Lisa Pont,** University of Technology Sydney	**Moderators:** **Frank May,** RGH Pharmacy Consulting Services **Prof Barbara Mintzes,** University of Sydney	**Moderators:** **Prof Shaun Lee,** Monash Malaysia **Prof Debra Rowett,** Adelaide University
09:00–09:15	**200. Impact of opioid stewardship on postoperative opioid prescribing patterns: interrupted time-series analysis** Dereje Assefa, Monash University	**206. Delphi consensus adapting international clinical standards for tuberculosis ADR management in Indonesia** Jasmine Aisyah, Universitas Padjadjaran	**212. Nationwide trends in biosimilar utilization and biologic expenditures following policy interventions** Yuexiang Ji, University of Tokyo	**218. Implementing standardised methods to measure post-stroke medication adherence in Australia and Canada** Dr Lachlan Dalli, Monash University
09:15–09:30	**201. Trends in pregabalin use and concurrent opioid and health service utilisation** Edward Chun Yin Lau, The University of Sydney School of Pharmacy	**207. Risk factors for extended carbapenem-resistant Enterobacteriaceae colonisation: case-control study on healthcare database Jack Chi Him Lau,** The University of Hong Kong	**213. Impact of China's pharmacovigilance legislation on medication safety: a litigation-based evaluation** Dr Xiaoxiao Li, Peking University Third Hospital	**219. Bridging the Treatment Gap in Dyslipidemia: A Multilingual, Pharmacist-Led Interventional Study Dr Ramesh Bhandari,** KLE College of Pharmacy Belagavi

Day 2 – Sunday 1 November 2026				
09:30–09:45	**202. Do comprehensive medication reviews impact concurrent gabapentin-opioid use in Medicare beneficiaries?** Dr Daniela Moga, University of Kentucky	**208. Uncovering real-world drivers of hepatitis C treatment failure in Pakistan** Dr Saima Mushtaq, Xi'an Jiaotong University	**214. Mapping public reporting of antibiotic shortage definitions, frequency, duration across OECD countries** Dr Chloe C. H. Smit, University of Technology Sydney	**220. Digital health competency and determinants among pharmacists in Indonesia: a national survey** Wardatul Jannah, Universitas Padjadjaran
09:45–10:00	**203. Segmented Trends in Pharmaceutical and Illicit Opioid Poisonings in Victorian EDs** Crystal Hiu Lam Leung, Monash University	**209. Pharmacovigilance signals and regional burden of antibiotic-associated Clostridioides difficile infection** Jaeyu Park, Kyung Hee University	**215. Prevalence and sociodemographic predictors of medication economic stress among chronic disease outpatients** Pamulapati Ajendra, JSS College Of Pharmacy	**221. Capability for real world monitoring of quality of medicines use: interview study** Judith Mackson, The University of Sydney
10:00–10:15	**204. Association between ambient temperature, hip-fracture, and sedative medication use: A case-crossover analysis** Sam Wade, Monash University	**210. Risk Factors For Children Staphylococcus Aureus and Antimicrobial-Resistance Carriage: A Case-Control Study** **Natalie Tsz Ying Tsie,** The University of Hong Kong	**216. Long-Term Healthcare and Societal Cost Burden of ADHD in Hong Kong** WaiKi Cheung, The University of Hong Kong	**222. National trends of potentially inappropriate medication use and costs among older Australians** **Yannee Liu,** Monash University
10:15–10:30	**205. Concurrent opioid or gabapentinoid use with benzodiazepines or anti-depressants: adverse outcomes** Dr Lauren Wearne, Registry of Senior Australians (ROSA) Research Centre, South Australian Health and Medical Research Institute	**211. Serious Infection after Denosumab versus Zoledronic Acid Discontinuation in Patients with Osteoporosis** Hui-Eon Lee, Ewha Womans University	**217. Trends in Publicly Subsidised and Private Access to GLP-1 Medicines in Australia** A/Prof Michael Falster, University of New South Wales	**223. Twelve-month adherence trajectories to SGLT2 inhibitors and GLP-1 receptor agonists in Australia** Thu Hang Nguyen, Monash University
10:30-10:55	**Morning Break / Exhibition / Poster Viewing**			

11:00-12:30	**Concurrent Symposium Session 7 - Integrating Machine Learning into Pharmacoepidemiology Methodology: Hybrid Research Approaches Across the Asia-Pacific**	**Concurrent Symposium Session 8 - Drug-Environment Interactions: Real-World Studies Across the Life Course**	**Concurrent Symposium Session 9 - Modernizing Safety Evaluation Using Real-World Data: Future Direction and Opportunity for Pharmacoepidemiologists**	**Contributed Paper Session 11 - Respiratory and Cardiopulmonary Outcomes**
Room:	**Lecture Theatre 3**	**Lecture Theatre 1**	**Lecture Theatre 5**	**Lecture Theatre 2**
	Moderators: **Dr Nathan Vidal**, National Cheng Kung University **Prof Edward Lai,** National Cheng Kung University **Speakers:** **Yifan Li,** The University of Hong Kong **Prof Aimin Yang,** The Chinese University of Hong Kong **Dr Richeek Pradhan,** Monash University	**Moderator:** **Lisa Pont,** University of Technology Sydney **Speakers:** **Dr Benjamin Bates,** Rutgers University **Dr Chloe C. H. Smit,** University of Technology Sydney **Yea-Huei Kao Yang,** National Cheng Kung University **Dr Lizbeth Gomez,** Rutgers University Center for Climate Health and Healthcare	**Moderator:** **Hiroshi Yamazaki,** Johnson & Johnson **Speakers:** **Dr Suguru Okami,** Bayer Yakuhin, Ltd. **Prof Ju-young Shin,** Seoul National University **Dr Qingqing Hu**, Johnson & Johnson **Dr K. Arnold Chan,** TriNetX	**Moderators:** **A/Prof Amy HY Chan,** The University of Auckland School of Pharmacy **Dr George Tan,** Monash University
11:00–11:15				**224. Cardiovascular risk after successive COPD exacerbations: dose-response analysis, New Zealand** Prof Jeff Harrison, University of Auckland
11:15–11:30				**225. Ethnic and socioeconomic disparities in COPD burden and cardiovascular outcomes, New Zealand** William Harrison, University of Auckland
11:30–11:45				**226. SGLT2 inhibitors and risk of idiopathic pulmonary fibrosis: A population-based cohort study** Minjeong Jeon, Sungkyunkwan University
11:45–12:00				**227. Thromboembolic risk after intravenous immunoglobulin therapy: a time-aligned cohort study** Brayden Gibson, Monash University

12:00–12:15				**228. Trend of severe VTE in locally advanced or metastatic NSCLC in Japan** Tomoaki Kono, Johnson & Johnson
12:15–12:30				**229. Early bleeding prediction in older patients anticoagulated for acute pulmonary embolism** Dr Yuzhi Tao, Peking University
12:30-13:55	**Lunch**			
12:45-13:55	**Poster Spotlight Session 2 (Please See Poster Program for Details)** **Group 1 – Pharmacy Practice and Drug Utilisation** **Group 2 – Effectiveness, Economics and Clinical Course**			
Room:	**Monash Connect**			
14:00-30	**Contributed Paper Session 12 - Biologics and Therapies for Immune-Mediated Disease**	**Contributed Paper Session 13 - Perinatal, Reproductive and Women's Health Pharmacoepidemiology**	**Contributed Paper Session 14 - Causal Inference, Prediction and Real-World Data Methods**	**Contributed Paper Session 15 - Emerging Medication Effects and Safety Signals**
Rooms:	**Lecture Theatre 3**	**Lecture Theatre 1**	**Lecture Theatre 2**	**Lecture Theatre 5**
	Moderators: **Dr Lizbeth Gomez,** Rutgers University **Dr K. Arnold Chan,** TriNetX	**Moderators:** **Dr Ruth Brauer,** UCL **A/Prof Michael Falster,** UNSW Sydney	**Moderators:** **Prof Edward Lai,** National Cheng Kung University **Prof Gillian Caughey,** Flinders University	**Moderators:** **Prof Ju-young Shin,** Seoul National University **Dr Richeek Pradhan,** Monash University
14:00–14:15	**230. Interstitial-Lung Disease risk of JAK inhibitors in Rheumatoid Arthritis using claim database** Dr Albert Tzu-Ming Chuang, National Cheng Kung University	**236. Examining trends in postpartum domperidone use in Australia: a retrospective cohort study** A/Prof Luke Grzeskowiak, Flinders University	**242. National oral health screening for oral cancer prevention: sequential target trial emulation** Areum Han, Seoul National University College of Medicine	**248. Increased ischemic risk with P-CAB or PPI in clopidogrel-treated stroke patients** Kyungwon Lee, Chung-Ang University

14:15–14:30	**231. Interactions between BMI and clinical characteristics in skin clearance among ustekinumab-treated psoriasis** Tong Li, Johnson & Johnson	**237. Examining variation in contraceptive prescribing in Australian general practice** Dr Gizat Molla Kassie, South Australian Health and Medical Research Institute Limited	**243. BRIDGE: barrier-informed Bayesian prediction of cardioprotective medication non-adherence trajectories in primary care** Dr Harvey Jia Wei Koh, Monash University	**249. Depression incidence following oral prophylactics and CGRP injection for migraine or headache** Cuiling Wei, The University of Hong Kong
14:30–14:45	**232. Clinical characteristics and treatment patterns of perianal Crohn's disease in Japan** Dr Li Yan, Johnson & Johnson	**238. Insights on perinatal psychotropic medicine use in a population-based Australian study** Dr Bianca Varney, University of New South Wales	**244. Methodological Gaps in Clone-Censor-Weight Approach for Target Trial Emulation: A Systematic Review** Prof Tengfei Lin, Southern Medical University	**250. Pharmacovigilance signals and global burden trends of epilepsy: Integrated FAERS-GBD 2023 analysis** Hyunyi Yoo, Kyung Hee University
14:45–15:00	**233. Ten-year cost savings associated with biosimilar tumour necrosis factor inhibitors** Chin Hang Yiu, The University of Sydney School of Pharmacy	**RISING STAR AWARDEE:** **239. Psychiatric disease relapse after antipsychotic discontinuation during pregnancy: a target trial emulation** Dr Vincent Ka Chun Yan, The University of Hong Kong	**245. Operationalizing Thyroid Eye Disease Identification in Taiwan Using Patient Journey-Based EHR Approach** Dr Daniel Tsai, National Cheng Kung University	**251. The real-world effectiveness of anti-osteoporosis medications in reducing incident dyslipidemia risk** Chun-Ta Peng, Fujen Catholic University
15:00–15:15	**234. Clinical and Developmental Outcomes of Cyclosporine versus Methotrexate in Pediatric Atopic Dermatitis** Vincent Ping-Sheng Chou, National Cheng Kung University	**240. Cardiovascular risk of menopausal hormone therapy in type 2 diabetes in England** Hindun Risni, University College London	**246. Development and Validation of Machine-Learning Prediction Models for Risperidone Response in Dementia** Harry Le, University of Sydney	**252. Beyond suspected drugs: class-level profiling of polypharmacy ADR reports** Hyeongjun Han, Pusan National University
15:15–15:30	**235. Real-World Sjögren's Syndrome Study using reginal electronic health record: Nanjing Retrospective Cohort** Yang Feng, Xiamen Chazen Biomedical Technology Co., Ltd.	**241. Prescription Patterns in Antipsychotic Use During Pregnancy: A 17-Year Population-based Study** Zi-Xian Wu, National Taiwan University	**247. Drug Repurposing for Dengue Fever Prevention Using Tree-Based Scan Statistics** Dr Albert Tzu-Ming Chuang, National Cheng Kung University	**253. Anticholinergic Medication-Class Patterns and Cardiovascular Risk in Older Adults: Group-Based Multi-Trajectory Analysis** Wen-Hsuan Liao, National Taiwan University

15:30-15:55	**Afternoon Break / Exhibition / Poster Viewing**
16:00-16:45	**Keynote Presentation**
Room:	**Lecture Theatre 3**
	Pharmacoepidemiology: Past, Present, and Future, and Selected Lessons from a Career in Pharmacoepidemiology **Prof Brian Strom,** Rutgers Biomedical and Health Sciences, Rutgers University
16:45-17:15	**Conference Close**
Room:	**Lecture Theatre 3**

Poster Summary

Location	Saturday	Sunday
Cossar Hall	Benefit-Risk Assessment, Communication and Evaluation (BRACE) Disease Epidemiology / Clinical Course Drug Effectiveness Drug Utilization Research	Health Equity Artificial Intelligence / Informatics / Digital Epidemiology Methods in Pharmacoepidemiology Molecular Epidemiology / Biomarkers / Pharmacogenetics Pediatric Pharmacoepidemiology Pharmacovigilance Pharmacy Practice and Pharmacoepidemiology
Cafeteria	Environmental Pharmacoepidemiology Geriatric Pharmacoepidemiology Health Economics / Outcomes Research	Pregnancy and Lactation Safety Outcomes Traditional and Alternative Medicines Vaccines Other related fields

Spotlight Poster Program

Saturday 31 October 2026

Group 1 - Effectiveness and safety outcomes	Location: Monash Connect
SP01	**Effectiveness and safety of statins in patients with type 1 diabetes mellitus** Joseph Blais, The University of Hong Kong
SP02	**Tyrosine kinase inhibitors and metabolic disease in chronic myeloid leukemia patients** Yi-Chou Chiu, National Yang Ming Chiao Tung University
SP03	**Granuloma recurrence post-cauterisation in peritoneal dialysis: a self-controlled case series analysis** Fei Yee Lee, Ministry of Health Malaysia
SP04	**SSRI use in the first trimester of pregnancy and risk of MCMs** Haruto Watanabe, Tohoku University
SP05	**Risk of cardiovascular events and methylphenidate/modafinil use in patients with narcolepsy** Daniel Tsai, National Cheng Kung University
SP06	**Benefit and risk of statins in young adults with diabetes** Eric Yuk Fai Wan, The University of Hong Kong
SP07	**Real-world effectiveness and safety of trastuzumab deruxtecan in non-small cell lung cancer** Heng Weng Lin, Chang Gung Memorial Hospital

Group 2 - Pharmacovigilance	Location: Monash Connect
SP08	**Development of signal prioritization system for Thailand's national pharmacovigilance program** Waranee Bunchuailua, Silpakorn University
SP09	**Second-line antidiabetic drugs and acute pancreatitis: absolute risk and self-controlled case series** Franco Cheng, The University of Auckland
SP10	**Azole-induced symmetrical drug-related intertriginous and flexural exanthema: A disproportionality analysis** Sonal Sekhar Miraj, Manipal Academy of Higher Education
SP11	**Pharmacovigilance of Chemotherapy-Induced ADRs in Breast Cancer: A Prospective Multicenter Study** Manjula Santhepete Nanjundaiah, JSS Academy of Higher Education and Research
SP12	**Mapping Methotrexate Toxicity in Pediatric Oncology: An Integrative Pharmacovigilance-Pharmacogenomic Database Study** Albin T Thottankara, Manipal Academy of Higher Education
SP13	**Alpelisib-associated diabetic ketoacidosis: FAERS analysis and systematic review** Meng-Hsuan Tsai, Kaohsiung Chang Gung Memorial Hospital
SP14	**Gabapentinoid poisoning presentations to Victorian emergency departments: a 15-year trend analysis** Ting Xia, Monash University

Spotlight Poster Program

Sunday 1 November 2026

Group 1 - Pharmacy practice and drug utilisation	Location: Monash Connect
SP15	**Global trends in Esketamine utilisation: An analysis of multinational sales data** Eunice Kehui Deng, The University of Hong Kong
SP16	**Socioeconomic and geographic inequities in access to Parkinson's disease treatment in NSW** Andrew Evans, The University of Melbourne
SP17	**Implementing WHO-Recommended Tuberculosis Dosing in Indonesia: A Qualitative TDF Study** Githa Fungie Galistiani, Universitas Muhammadiyah Purwokerto
SP18	**Predictors of persistent benzodiazepine prescriptions in Australian primary care** Monica Jung, Monash University
SP19	**Closed-loop real-time allergy communication to prevent repeat drug allergy exposure** Panita Kapol, Nakhon Pathom Hospital
SP20	**Trends in contraceptive prescribing in Australian general practice: A longitudinal national study** Gizat Molla Kassie, South Australian Health and Medical Research Institute
SP21	**Workflow-embedded automation improves hepatitis B screening and safety in b/tsDMARD users** Meng Hsuan Kuo, Dalin Tzu Chi Hospital

Group 2 - Effectiveness, economics and clinical course	Location: Monash Connect
SP22	**Comparative effectiveness of atezolizumab plus bevacizumab versus lenvatinib in advanced hepatocellular carcinoma** Hui-Yu Chen, Linkou Chang Gung Memorial Hospital
SP23	**Real-world outcomes of sacubitril-valsartan for treatment of heart failure in Singapore** Shi Thong Heng, Agency for Care Effectiveness
SP24	**Sulfonylurea use and vascular complications in type 2 diabetes** Di Liu, University of Macau
SP25	**Cost-utility analysis of subdural electrode and stereo-electroencephalography monitoring for drug-resistant epilepsy patients** Nattiya Kapol, Silpakorn University
SP26	**PPCVD-HEM+: GPU microsimulation and Monte Carlo tree-search optimisation for cardiovascular prevention** Harvey Jia Wei Koh, Monash University
SP27	**Sequence matters: trajectories,velocities, and competing mortality risks in type 2 diabetes complications** Pornpun Chalermrum, Ubon Ratchathani University
SP28	**GLP1R–SLC5A2 interactions and kidney function in Mendelian randomization** Chenyuan Yan, University of Nottingham Ningbo China & SUAT

Poster Program

Saturday 31 October 2026

Benefit-Risk Assessment, Communication and Evaluation	Location: Cossar Hall
D1/P100	**Whitening cosmetic advertisements on TikTok: violations of Thailand's Cosmetics Act** Sirikanlaya Benjawan, Silpakorn University

Disease Epidemiology / Clinical Course	Location: Cossar Hall
D1/P101	**Prevalence and clinical profile of heart failure in hospital inpatients** Naga Sai Rishitha Chintamaneni, JSS Academy of Higher Education and Research
D1/P103	**Net reclassification of P-CARDIAC for clinical stability among patients with prior CVD** Sze Ling Celine Chui, The University of Hong Kong
D1/P104	**Six-Year Surveillance Reveals Escalating Antifungal Resistance in Hospitalized Patients** Kiran Khanna Dayabaran, Sri Ramachandra Institute of Higher Education and Research
D1/P105	**Health service utilisation prior to drug-related deaths: a systematic review and meta-analysis** Khine Wut Yee Kyaw, UNSW Sydney
D1/P106	**Incidence surveillance for extended Carbapenem-Resistant Enterobacteriaceae colonisation: an Interrupted time series** Jack Chi Him Lau, The University of Hong Kong
D1/P107	**Associations of CAD genetic risk-driven proteins with MASLD and liver-related events** Di Liu, University of Macau
D1/P108	**Nutritional Status and Renal Function as Determinants of Geriatric Fragility Fractures** Kenji Momo, Showa Medical University
D1/P109	**BRI vs. BMI for predicting the incident diabetes and hypertension: SKDB study** Masato Takeuchi, Shizuoka Graduate University of Public Health
D1/P110	**Latent class analysis-derived multimorbidity patterns and mortality in pharmacologically-treated type-2-diabetes in Australia** Sam Wade, Monash University
D1/P111	**Obesity phenotypes and cardiovascular risk in metabolic dysfunction–associated steatotic liver disease** Yu-Syuan Wang, National Yang Ming Chiao Tung University
D1/P112	**Physical Frailty, Genetic Susceptibility, and Osteoporosis Risk: A Cohort Study** Dongxue Wang, University of Macau
D1/P113	**Path-specific effects of persistent pain on incident hearing difficulty through time-varying mediators** Bin Xu, The Second Qilu Hospital of Shandong University

Drug Effectiveness	Location: Cossar Hall
D1/P114	**Real-World Renal Outcomes of Sglt-2 Inhibitors In Diabetic Kidney Disease** Rachitha B M, JSS Academy of Higher Education and Research
D1/P115	**Alzheimer's and Dementia Risk: JAK Inhibitors vs Abatacept in Rheumatoid Arthritis** Min-Hung Chang, National Cheng Kung University
D1/P116	**Real-world effectiveness of enfortumab vedotin plus immunotherapy for urothelial cancer in Taiwan** Yu-Hsuan Chen, National Yang Ming Chiao Tung University
D1/P117	**Treatment patterns and outcomes of neoadjuvant durvalumab plus GC in MIBC** Pong-Hsin Chien, National Yang Ming Chiao Tung University
D1/P118	**Systematic Review of Chemotherapy-Induced Toxicities in Cervical Cancer Patients** Sanjay Jayaram, JSS Academy of Higher Education and Research
D1/P120	**Sequential versus Concurrent Immunotherapy-Radiotherapy in Solid Tumors: Network Meta-Analysis** Doran Kim, Chung-Ang University
D1/P121	**Efficacy of iguratimod for treating rheumatoid arthritis: a systematic review and meta-analysis** Mahsa Kouhkamari, IQVIA
D1/P122	**Vitamin D supplementation and cardiovascular disease progression in prediabetes: a multi-state analysis** Jianzhao Liu, Southern University of Science and Technology
D1/P123	**Mebeverine versus otilonium bromide for quality-of-life outcomes in irritable bowel syndrome** Anh Thi Phuong Luu, University of Medicine and Pharmacy
D1/P124	**Real-world streptokinase outcomes in acute myocardial infarction** Saima Mushtaq, Xi'an Jiaotong University
D1/P125	**Impact of Semaglutide on Diabetic Microvascular Complications: A Systematic Review and Meta-Analysis** Aarathy S Nair, Manipal Academy of Higher Education
D1/P126	**Combined effects of statin adherence and PCSK9 inhibitor persistence on post-revascularization outcomes** Siqi Ni, Tianjin University
D1/P127	**Efficacy and safety of treatments for idiopathic pulmonary fibrosis: a network meta-analysis** Narisa Ruenroengbun, Silpakorn University

Drug Utilization Research	Location: Cossar Hall
D1/P128	**Determinants of diabetes medication adherence across ABC taxonomy phases: an umbrella review** Sofa Dewi Alfian, Universitas Padjadjaran
D1/P129	**Age-specific trends and projections in insulin use in Hong Kong: 2002-2030** Xiuyuan Bai, The Chinese University of Hong Kong
D1/P130	**Utilisation pattern and costs of first-line antiseizure medications in Australia** Nega Dagnew Baye, Monash University
D1/P131	**Uptake of longer prescription durations for type 2 diabetes in Australia** Juliana de Oliveira Costa, UNSW Sydney
D1/P132	**Potentially inappropriate prescribed medicines among people hospitalised with heart failure in Australia** Michael Falster, UNSW Sydney
D1/133	**Economic development, ADHD-related disease burden, and medication utilization in China: a correlational analysis based on provincial level data** Le Gao, Xi'an Jiaotong University
D1/P134	**Suboptimal antiretroviral treatment patterns in Australian dispensing data** Leping (Victor) Kong, The University of Sydney
D1/P135	**How do clinical guidelines support appropriate use of ketamine/esketamine for depression** Kyungmin (Kirsten) Lee , Monash University
D1/P136	**Patterns of psychotropic dispensing among people with and without intellectual disability** Peiwen Liao, UNSW Sydney
D1/P138	**Evolving glucose-lowering drug use after metformin: A nation-wide study in Australia** Thu Hang Nguyen, Monash University
D1/P139	**Trends in oral anticoagulant use among US adults with chronic diseases, 2009-2020** Trang Nguyen, University Medical Center Ho Chi Minh City
D1/P140	**A retrospective drug utilization review of restricted antibiotics in a government hospital** Imelda Peña, University of the Philippines
D1/P141	**Antibiotic Dispensing Patterns and AWaRe Utilization in Community Pharmacies** Meenakshi Sanilal, JSS Academy of Higher Education and Research
D1/P142	**Effect of drug utilization review on prescription of long-acting benzodiazepines to elderly** Sun Mi Shin, Korea Institute of Drug Safety and Risk Management
D1/P143	**Impact of subsidy listing on biosimilar trastuzumab adoption in HER2+ breast cancer** Yilin Sng, Agency for Care Effectiveness
D1/P144	**Global trends in consumption and expenditure of GLP-1-based therapies, 2015–2024** Jing Sun, The University of Hong Kong
D1/P145	**Adherence trajectories to secondary prevention after ischemic stroke and cardiovascular outcomes** Shih-Wei Wang, Kaohsiung Chang Gung Memorial Hospital
D1/P146	**Real-world risk of hepatitis B reactivation in patients receiving Janus kinase inhibitors** Chen-Yi Wu, Dalin Tzu Chi Hospital

D1/P147	**Understanding the barriers to medication adherence in patients with uncontrolled asthma** Yingqi Xu, Singapore Health Services
D1/P148	**Trends and Risk Factors for Severe Hypoglycemia in Human and Analogue Insulin** Aimin Yang, The Chinese University of Hong Kong

Environmental Pharmacoepidemiology	**Location: Cafeteria**
D1/P149	Demographic and Environmental Risk Factors Associated with Japanese Encephalitis Exposure in Asia **Narmatha Rajarathinam, Sri Ramachandra Institute of Higher Education and Research**

Geriatric Pharmacoepidemiology	**Location: Cafeteria**
D1/P150	**Polypharmacy and excessive polypharmacy among older adults in Indonesian residential aged-care facilities** Siti Dwi Astuti, Monash University
D1/P151	**Impact of Post-Discharge Reviews on Potentially Inappropriate Glucose-Lowering Medication Use** Darshna Goordeen, Monash University
D1/P152	**Latent class analysis of neuropsychiatric symptoms in dementia** Harry Le, The University of Sydney
D1/P153	**Longitudinal trajectories of anticholinergic burden and dementia risk among older adults** Yuan-Zhi Lin, National Yang Ming Chiao Tung University
D1/P154	**Melatonin Use in Australian Residential Aged Care: Prevalence and Psychotropic Co-Prescribing** Yuxing Liu, Monash University
D1/P155	**Changes in prescription cannabinoids and analgesic medications among US nursing home residents** Colleen Maxwell, University of Waterloo
D1/P156	**Association of benzodiazepines with fractures among older Japanese inpatients: a new-user study** Akemi Nitta, Kansai Medical University
D1/P157	**Association rule mining of medication combinations in older adults with continuous polypharmacy** Edwin Tan, The University of Sydney
D1/P158	**Dual orexin receptor antagonists and the risk of incident dementia** Nathan Vidal, National Cheng Kung University
D1/P159	**National Antibiotic Trends among Long-term Care Facilities by Prescribing Survey Participation, 2016-2022** Yohanes Wondimkun, Adelaide University

Health Economics / Outcomes Research	Location: Cafeteria
D1/P160	**Cost-related nonadherence to medications among pregnant women: Findings from the U.S. NHIS** Chloe Chen, National Yang Ming Chiao Tung University
D1/P161	**Introducing non-contrast magnetic resonance imaging surveillance for hepatocellular carcinoma in cirrhosis** Yeonggyeong Jang, Seoul National University
D1/P162	**Cost-Effectiveness and Clinical Outcomes of Perioperative Immunotherapy in Advanced Unresectable Head-Neck Cancer** Avinash Khadela, Parul University
D1/P163	**Optimal age of Helicobacter pylori eradication for gastric cancer prevention in Korea** Seongeun Lee, Seoul National University
D1/P165	**Topical Hemostatic Material Use, Major Bleeding, and Healthcare Burden in Hepatectomy** Shiori Nishimura, The University of Tokyo
D1/P166	**Network meta-analysis of pharmacological treatments for hypersensitivity pneumonitis** Kamolpat Russameeruttayadham, Silpakorn University
D1/P167	**Medication economic stress drives intentional non-adherence: The MESDS development study** Prem S Nijesh, JSS Academy of Higher Education and Research
D1/P168	**Phase-4 Non-Inferiority Trial assessing Cost-Effectiveness of Conventional versus Super-Bioavailable Itraconazole in Dermatophytosis** Vraj B Shah, LM College of Pharmacy
D1/P169	**Mixed-method evaluation of a digital health and community pharmacy-supported prediabetes management program** Kah Woon Teoh, Monash University
D1/P171	**Health productivity impact of risk thresholds for primary prevention of cardiovascular disease** Karl Vivoda, Monash University
D1/P172	**Disease Burden And Healthcare Utilization Of Glioma In China: A Cohort Study** Hanyi Wang, Peking University
D1/P173	**Hidden Costs of Breast Cancer Care in Indonesia: Direct Non-Medical Expenses** Rizka Prita Yuliani, Monash University

Poster Program

Sunday 1 November 2026

Health Equity		Location: Cossar Hall
D2/200	**Barriers And Enablers to Cardiovascular Medication Adherence: A Qualitative Evidence Synthesis** Caroline Trin, Monash University	
D2/201	**Social trust correlates of hard drug use among U.S. adults** Hongru Zou, The Chinese University of Hong Kong	

Artificial Intelligence / Informatics / Digital Epidemiology		Location: Cossar Hall
D2/202	**Hospital Pharmacists' Experience, Perception, Readiness in Shifting from Rule-Based to AI-Driven CDSS** Ayu Andayani, Monash University	
D2/203	**Trends in AI-Assisted Medication: A Scoping Review Facilitated by Large Language Models** Jiaxin Cai, Shenzhen University of Advanced Technology	
D2/204	**Estimating Individualized Treatment Effects of Methylphenidate: A Causal Machine Learning Approach** Eunkang Kim, Ajou University	
D2/205	**Generalizability of an AI-driven P-CARDIAC cardiovascular risk model in diverse subpopulations** WaiKi Cheung, The University of Hong Kong	
D2/206	**Artificial intelligence for medication safety in older adults: a scoping review** Min-Gyu Kang, The University of Sydney	
D2/207	**Digital Epidemiology of Medication Adherence in Indonesia: Infodemiology Study Using X Data** Qisty A Khoiry, Universitas Padjadjaran	
D2/208	**ICI prediction model reporting quality before and after TRIPOD+AI: a pilot study** Yousong Lee, Chung-Ang University	
D2/209	**Enhancing Opioid Overdose Identification in Emergency Department Data via Natural Language Processing** Crystal Hiu Lam Leung, Monash University	
D2/210	**Ai-Adhere: AI-Driven Real-Time Framework for Medication Adherence Assessment in Chronic Conditions** Shilpa Palaksha, JSS Academy of Higher Education and Research	
D2/211	**AI-Enabled inhaler technique assessment and adherence monitoring in asthma and COPD** Shilpa Palaksha, JSS Academy of Higher Education and Research	
D2/212	**Design and validation of an intelligent medication-safety application** Vishnu Santhosh, JSS Academy of Higher Education and Research	
D2/213	**Machine Learning-Derived Trauma Mortality Prediction and Risk Stratification in Asia** Ruth Sim, Monash University	

Methods in Pharmacoepidemiology	Location: Cossar Hall
D2/214	**Developing a claims-based algorithm to identify infection in multiple myeloma** Hsu-Wen Chou, Pfizer
D2/215	**BRAVE Protocol: Utilising HDSS for Active Monitoring of AESI Background Rates** Hazel Clothier, Murdoch Children's Research Institute
D2/216	**Estimands in Prevalent New User Designs: Clarifying Treatment Effects and Target Populations** Kelly Hall, Adelaide University
D2/217	**SGLT-2i and Risk of VTE in T2DM: A Target Trial Emulation Study** Yuhao Li, Peking University
D2/218	**Psychiatric adverse events of antiepileptic drugs: disproportionality analysis and risk prediction** Jeongseon Oh, Kyung Hee University
D2/219	**Estimating the average treatment effect using disease risk score weighting methods** Midori Ota, Yokohama City University
D2/220	**Building reproducible paediatric medication safety studies using OMOP common data model** Diana Vlasenko, Murdoch Children's Research Institute

Molecular Epidemiology / Biomarkers / Pharmacogenetics	Location: Cossar Hall
D2/221	**Vitamin D supplementation associated with vitamin D–VDR–LL37 pathway and diabetic foot healing** Ruby Benson, Manipal Academy of Higher Education
D2/222	**Real-world evidence and pharmacoepidemiologic implications of hepatitis-associated HCC and viral persistence** Saima Mushtaq, Xi'an Jiaotong University

Pediatric Pharmacoepidemiology	Location: Cossar Hall
D2/223	**Impact of valproic acid concentration on BMI z-score and pediatric hyperammonemia** Chiu-Ju Chen, Kaohsiung Chang Gung Memorial Hospital & Chang Gung University
D2/224	**Prenatal antiseizure medication exposure and risk of neuropsychiatric disorders in children** Yeona Jo, Kyung Hee University
D2/225	**Risk Factors For Antimicrobial-Resistant Escherichia Coli Carriage In Children: A Case-Control Study** Natalie Tsz Ying Tsie, The University of Hong Kong

Pharmacovigilance	Location: Cossar Hall
D2/227	**Aligning People, Not Just Protocols: Integrating Cultural Awareness into Multi-Country Pharmacovigilance Collaboration** Jim Buttery, Global Vaccine Data Network
D2/228	**Evaluating electronic health record readiness for vaccine safety surveillance in resource-limited settings** Jim Buttery, Global Vaccine Data Network
D2/229	**Identifying post-HPV vaccination safety mentions using natural language processing in Indonesia** Jarir At Thobari, Universitas Gadjah Mada
D2/230	**Real-World Treatment Patterns and Cardiovascular Outcomes Among Romosozumab Users** Yuwen Chang, Kaohsiung Chang Gung Memorial Hospital
D2/231	**Protamine and naloxone trigger tools for detecting preventable adverse drug reactions** Panita Kapol, Nakhon Pathom Hospital
D2/232	**Adverse Drug Reactions Associated with Mucolytic Agents: A 10-Year Retrospective Study** Cheol-Woo Kim, Inha University Hospital
D2/233	**Eravacycline Treatment Causes a Decrease in Fibrinogen Levels** Xiaohua Liu, The First Affiliated Hospital of Nanjing Medical University
D2/234	**Assessment of Adverse Drug Reaction Preventability: Comparison of LAAT and Schumock-Thornton Scales** Raghava Kalyan Maddukuri, Chebrolu Hanumaiah Institute of Pharmaceutical Sciences
D2/235	**From signal detection to label change: a DME-based pharmacovigilance system in Korea** Sun Mi Shin, Korea Institute of Drug Safety and Risk Management

Pharmacy Practice and Pharmacoepidemiology	Location: Cossar Hall
D2/236	**Assessment of PCOS prevalence and mental health impact among students** Ganavi B R, JSS college of Pharmacy, Mysore
D2/237	**Polypharmacy and clinical predictors of mortality in an ambispective heart failure cohort** Tenzin Dhasel, JSS Academy of Higher Education and Research
D2/238	**Opioid use in people living with dementia: a scoping review** Hoda Fahmy, The University of Auckland
D2/239	**Assessment of medication adherence and quality of life among cancer patients** Aishwarya Ge, Dayananda Sagar University
D2/240	**Impact of clinical pharmacist services on quality of life in tinea patients** Pratiksha Nagesh Kini, KLE College of Pharmacy
D2/241	**Simulation-Based Assessment Tools for Pharmacy Competency in OTC Self-Medication: Development and Validation** Bhavya L K, JSS College of Pharmacy, Ooty
D2/242	**Medication literacy failures among ethnic minority adults in Southern India** Shawn Lopes, JSS Academy of Higher Education and Research
D2/243	**Candida auris: isolation and susceptibility in a Chinese tertiary teaching hospital** Can Luo, The First Affiliated Hospital of Nanjing Medical University

D2/244	**Prescribing Appropriateness for Type 2 Diabetes Mellitus at Military Hospital 175, Vietnam** Dung Thi Ngoc Tran, University of Medicine and Pharmacy
D2/245	**Considerations for research with industry-affiliated patient representatives: insights from an Australian survey** Barbara Mintzes, The University of Sydney
D2/246	**Real-World Evidence of Missed Treatment Opportunities in Non-Transplant Newly Diagnosed Multiple Myeloma** Meng Shu, Johnson & Johnson

Pregnancy and Lactation	**Location: Cafeteria**
D2/247	**Biologics use and adverse fetal outcomes among pregnant women with asthma** Taiga Kondo, Showa Pharmaceutical University
D2/248	**Antidepressant use and miscarriage: a cohort study with stepwise confounding control** HyunJoo Lim, Sungkyunkwan University
D2/249	**Meta-analysis of Kampo medicines containing ephedra and Congenital Malformations** Aoi Noda, Tohoku Medical Megabank Organisation
D2/250	**Association between first-trimester bromhexine/ambroxol exposure and major congenital malformations** Takamasa Sakai, Meijo University
D2/251	**Perinatal pharmacoepidemiology in Japan: data sources and methodological challenges** Masami Tsuchiya, Keio University

Safety Outcomes	Location: Cafeteria
D2/252	**Medication Errors in Malaysia: a retrospective analysis from the national database 2013-2023** Norazida Ab Rahman, Utrecht University
D2/253	**SGLT2 inhibitors and infection-related hospitalisations in type 2 diabetes** Maria Jose Alfonso Arvez, Monash University
D2/254	**AKI risk with single-dose aminoglycoside in emergency departments among patients with CKD** Louri Banakh, Monash Health
D2/255	**Short-term risk of falls among initiators of controlled-release tapentadol versus oxycodone** Ximena Camacho, UNSW Sydney
D2/256	**Risk of opioid-induced nausea and vomiting after abdominal hysterectomy: a meta-analysis** Sueyoung Cho, Seoul National University
D2/257	**Correlation of Linezolid Trough Concentrations with Serum Lactate in Critically Ill Patients** Jing Hu, The First Affiliated Hospital of Nanjing Medical University
D2/258	**Bleeding and recurrent VTE associated with DOACs versus LMWH for cancer-associated thrombosis** Yichen Jin, The University of Hong Kong
D2/259	**Incidence of septic arthritis after intra-articular injection for knee osteoarthritis** Heeyeon Lee, Chung-Ang University
D2/260	**Risk of finasteride on metabolic dysfunction-associated steatotic liver disease and progression** Yuhao Li, Peking University
D2/261	**Sorafenib adverse events and quality-of-life trajectories in advanced hepatocellular carcinoma** Saima Mushtaq, Xi'an Jiaotong University

Traditional and Alternative Medicines	Location: Cafeteria
D2/262	**Protective Effects of Ocimum sanctum Against Diabetic Neuropathy and Cognitive Impairment** Pooja G Achar, JSS Academy of Higher Education and Research
D2/263	**Network Pharmacology And In Vitro Studies Reveal Piperine's Novel Parkinson's Disease Pathways** Chethan K S, JSS College Of Pharmacy, Mysuru
D2/264	**Therapeutic evaluation of traditional formulation of Caesalpinia bonducella in management of Sciatica** Mruthunjaya Kenganora, JSS Academy of Higher Education and Research

Vaccines	Location: Cafeteria
D2/265	**Sex Matters in Vaccine Pharmacovigilance** Hazel Clothier, Murdoch Children's Research Institute
D2/266	**Methodological approaches to long-term vaccine safety assessment in observational studies: Systematic review** Haeun Jo, Ewha Womans University
D2/267	**Assessing feasibility of Zhejiang platform for HPV vaccine effectiveness evaluation in China** Yuxia Liang, Zhejiang Provincial Center for Disease Control and Prevention
D2/268	**Do Not Pass Go (Without Reading This): Linked Data Pharmacovigilance Lessons Learned** John Mallard, Murdoch Children's Research Institute

Other related fields	Location: Cafeteria
D2/269	**Safety and efficacy of medications for urinary incontinence in people with dementia** Nileshni Fernando, Monash University
D2/270	**Comparing Decentralized Clinical Trial Regulatory Frameworks: United States vs. Australia** Jonghyeok Kim, Chung-Ang University
D2/271	**Antibiotic knowledge, attitude, and behaviour among residents of Nakhon Pathom, Thailand** Sineenart Krichanchai, Silpakorn University
D2/272	**Quantifying Regulatory Bottlenecks in South Korea's Clinical Trial Approval Process using AHP** Riyan Quan, Chung-Ang University
D2/273	**Regulatory Outcomes and Timelines of FDA Accelerated Approvals for Non-Oncology Therapeutics** Karunia Ayu Septanadhira, Chung-Ang University

Thank you to our Host Organisations:

ispe International Society for Pharmacoepidemiology

MONASH University

MONASH INSTITUTE OF PHARMACEUTICAL SCIENCES

Thank you to our Gold Sponsor:

MONASH University MONASH CENTRE FOR MEDICINE USE AND SAFETY

CENTRE FOR MEDICINE USE AND SAFETY

The Centre for Medicine Use and Safety (CMUS) is focused on innovative research to promote safe and effective medicine use. CMUS runs major national and international collaborative and multidisciplinary projects. CMUS has research strengths in:

- Pharmacoepidemiology
- Health economics
- Pharmacometrics
- Clinical practice guideline development
- Health services research
- Aged care research

monash.edu/mips/themes/medicine-safety



CRICOS provider: Monash University 00008C.